Look for Drugs and Conditions

Remogliflozin etabonate

Remogliflozin etabonate

Remogliflozin, a novel, highly selective inhibitor of sodium-glucose cotransporter subtype 2 (SGLT2)


Type 2 diabetes mellitus


oral; 100mg twice a day



Special Precautions

Paediatric: Safety and efficacy in pediatric patients have not been established Pregnancy: Data not sufficient Lactation: Data not sufficient Elderly: Data not sufficient

Side Effects

Low blood sugar (hypoglycemia), Urinary tract infections, Nervousness or anxiety, Irritability to sweat, Weight loss, Dizziness or headache, Fatigue, genital fungal infection

Drug Interactions

other hypoglycemic drugs

Other Combination Brands
Brand Name Manufactured by
REFOZI-M CARDIMIND PHARMACEUTICALS (A Division of Asterisk Laboratories Pvt Ltd)
Ad 5